Revenue from Contracts with Customers Revenue from Contracts with Customers (Notes)

6 Months Ended

Jun. 27, 2025

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

4. Revenue from Contracts with Customers

Product Sales Revenue

See Note 15 for disaggregation of the Company's net sales by product family.

Reserves for variable consideration

The following table reflects activity in the Company's sales reserve accounts:

	Rebates and Chargebacks (1)		Product Returns		Other Sales Deductions		Total
Balance as of December 29, 2023	$	201.6	$	14.5	$	11.3	$	227.4
Provisions	832.7		11.0		25.5		869.2
Payments or credits	(811.0)		(9.6)		(26.2)		(846.8)
Balance as of June 28, 2024	$	223.3	$	15.9	$	10.6	$	249.8
Balance as of December 27, 2024	$	197.5	$	14.8	$	16.5	$	228.8
Provisions	804.7		6.7		30.6		842.0
Payments or credits	(746.4)		(4.9)		(29.2)		(780.5)
Balance as of June 27, 2025	$	255.8	$	16.6	$	17.9	$	290.3

(1)Amounts classified within accrued and other current liabilities in the unaudited condensed consolidated balance sheets are comprised of $24.4 million and $26.4 million of accrued Medicaid and $89.5 million and $61.4 million of accrued rebates, of which $63.2 million and $39.8 million related to Acthar Managed Care and Medicare, as of June 27, 2025 and December 27, 2024, respectively. The change in accrued Medicaid and accrued rebates was reflected within other changes in assets and liabilities within the unaudited condensed consolidated statement of cash flows for the six months ended June 27, 2025.

Product sales transferred to customers at a point in time and over time were as follows:

	Three Months Ended				Six Months Ended
	June 27, 2025		June 28, 2024		June 27, 2025		June 28, 2024
Product sales transferred at a point in time	87.2	%	86.9	%	86.3	%	85.8	%
Product sales transferred over time	12.8		13.1		13.7		14.2

Transaction price allocated to the remaining performance obligations

The following table includes estimated revenue from contracts extending greater than one year for certain of the Company's hospital products that are expected to be recognized in the future related to performance obligations that were unsatisfied or partially unsatisfied as of June 27, 2025:

Remainder of Fiscal 2025	$	37.8
Fiscal 2026	65.7
Fiscal 2027	28.5
Thereafter	11.3

Costs to fulfill a contract

As of June 27, 2025 and December 27, 2024, the total net book value of the devices used in the Company's portfolio of drug-device combination products, which are used in satisfying future performance obligations and reflected in property, plant and equipment, net, on the unaudited condensed consolidated balance sheets was $45.9 million and $37.8 million, respectively. The associated depreciation expense recognized was as follows:

	Three Months Ended				Six Months Ended
	June 27, 2025		June 28, 2024		June 27, 2025		June 28, 2024
Depreciation expense	$	1.4	$	0.3	$	2.9	$	0.7